Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases
08 avr. 2021 18h58 HE
|
BioAegis Therapeutics
Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression. Gelsolin is non-immunosuppressive unlike current treatments to quell...
Velano’s PIVO™ Named 2018 MedTech Breakthrough Awards’ Best Overall Medical Device Solution
06 juin 2018 13h06 HE
|
Velano Vascular
SAN FRANCISCO, June 06, 2018 (GLOBE NEWSWIRE) -- Vascular access technology innovator Velano Vascular’s PIVO™ needle-free device for blood draws was named Best Overall Medical Device Solution by the...
Velano Vascular Named 2018’s Gold Edison Award™ Winner
17 avr. 2018 08h00 HE
|
Velano Vascular
SAN FRANCISCO, April 17, 2018 (GLOBE NEWSWIRE) -- Vascular access technology innovator Velano Vascular today announced that its PIVO™ needle-free device for blood draws was named the 2018 Gold...
Velano Vascular to Address Healthcare Innovation at Upcoming Spring Conferences
10 avr. 2018 08h00 HE
|
Velano Vascular
SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Vascular access technology innovator Velano Vascular today announced that company leadership will present at a number of premier healthcare...
Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference
25 oct. 2016 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease
13 avr. 2016 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., April 13, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease
08 janv. 2015 16h30 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Pricing of Initial Public Offering
21 oct. 2014 19h36 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc., a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and...
Pomona Valley Hospital Medical Center Unveils Life-Saving Tools for Victims of Stroke and Other Vascular Conditions
09 juin 2014 15h08 HE
|
Pomona Valley Hospital Medical Center - MNews
POMONA, Calif., June 9, 2014 (GLOBE NEWSWIRE) -- The chance of surviving a stroke can be increased if the victim gets help right away. Today, Pomona Valley Hospital Medical Center (PVHMC) announced...
TissueGen Enhances Intellectual Property Portfolio With New Patent for Self-Expanding Medical Device
29 avr. 2014 10h00 HE
|
TissueGen Inc.
DALLAS, TX--(Marketwired - Apr 29, 2014) - TissueGen® Inc., developer of cutting-edge biodegradable polymer technology for implantable drug delivery across a wide variety of therapeutic...